The safety and efficacy of these investigational agents have not been established.
Our portfolio of phosphodiesterase type 1 (PDE1) inhibitors are being explored for the treatment of various central nervous system (CNS) and non-CNS disorders.
Inhibitors of PDE1 block the breakdown of cyclic nucleotides (cAMP, cGMP), potentiating downstream intracellular signaling. The PDE1 enzyme has been shown in vitro to be highly active in a variety of disease states. We are investigating our PDE1 inhibitors to restore normal function in these disease states. PDE1 inhibitors appear to have minimal effect on normal cell function, only acting when cells are stimulated in vitro.
Our portfolio of phosphodiesterase type 1 (PDE1) inhibitors are being explored for the treatment of various central nervous system (CNS) and non-CNS disorders.
Lenrispodun (ITI-214) is a potent and selective PDE1 inhibitor and the clinical lead compound in the Company’s PDE1 portfolio. Lenrispodun is being investigated to treat a variety of neurological, cardiovascular and immune system diseases. It is currently in development for the treatment of symptoms associated with Parkinson’s disease and for the treatment of heart failure.